American BriVision Corporation, a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, announced it has postponed the public offering of its Series A Convertible Preferred Stock until a more opportune time.
February 25, 2020
· 4 min read